ClinicalTrials.gg
TerminatedNCT00635531Updated Jan 28, 2021

A Study to Evaluate the Use of Extended Release Alprazolam in the Treatment of Adolescents With Panic Disorder

A Phase 4 interventional study of placebo and alprazolam XR in Panic Disorder, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Terminated at 18 sites in United States. Open to participants aged 13 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-01-28.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment

Why this study was terminated
Please see Detailed Description for termination reason.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
13 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 109 studies in Panic Disorder with a site in United States — 9 open to participants now, 13 under way, none of them phase 3. Panic Disorder · United States.

Enrollment
84th of 94
16 · median 69
Started
2004
with 8 others
Phase 4
18 of 109
none open now
Registered
40th of 109
by date

Among the 109 studies in Panic Disorder with a site in United States, this one is the 84th largest by enrollment of the 94 interventional ones that give a count, is one of 9 that started in 2004, is one of 18 in phase 4, and was the 40th registered.

Panic Disorder

270 studies on the registry are indexed under Panic Disorder; 37 are open to participants now.

Browse Panic Disorder studies →

Open to participants now

9 of the 109 studies in Panic Disorder with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 24 Panic Disorder studies recruiting now, 8 (33%) set no upper age limit and 15 (63%) stop at 75 or younger; 6 take children under 18; 3 take healthy volunteers.

This study: 13 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 109 studies in Panic Disorder with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics of alprazolam extended release (XR) for the treatment of adolescents with panic disorder

Read the detailed description

Due to recruitment difficulties in this adolescent population, the clinical program for alprazolam XR was cancelled and this study was terminated on 1 September 2004. There were no safety concerns that led to this decision.

03

Conditions studied

  • Panic Disorder

Browse trials for

04

Who can participate

Ages eligible
13 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A primary diagnosis of panic disorder with or without agoraphobia based on the Mini International Neuropsychiatric Interview for Children and Adolescents
  • At least an average of one 4-symptom panic attack per week over the last 4 weeks prior to screening
  • At least an average of one 4-symptom panic attack per week over the last 4 weeks prior to baseline
  • At least one 4-symptom panic attack in the 7 days prior to baseline

Exclusion criteria

Exclusion Criteria:

  • Current (in the past 6 months) diagnosis of obsessive compulsive disorder, major depressive disorder, dysthymic disorder, or alcohol and/or substance dependence
  • Primary DSM-IV-TR diagnosis of social anxiety disorder, post-traumatic stress disorder, simple phobia, separation anxiety disorder, generalized anxiety disorder, conduct disorder, oppositional defiant disorder, or attention deficit hyperactivity disorder
  • Any current or past history of schizophrenia or psychosis; bipolar disorder or cyclothymia; dementia, delirium or other organic brain disease; an Axis I eating disorder; mental retardation, Asperger's disorder, or any other serious developmental disorder
  • A CDRS-R score >35
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
16 participants (actual)

Study arms

  • Placebo comparator
    Placebo group

    Other: placebo

  • Active comparator
    Alprazolam XR group

    Drug: alprazolam XR

Interventions

  • Otherplacebo

    Placebo dosing same as alprazolam, except a placebo equivalent was substituted for alprazolam

  • Oral treatment started at a daily dose of 1 mg tablets for the first 7 days; thereafter the daily dosage was titrated at a maximum rate of 1 mg every 7 days up to a maximum dosage of 6 mg for lack of response, and in the absence of dose-limiting adverse events; no further increases in daily dose were permitted after Day 36; dosage reductions were permitted if required for tolerability; subjects who were not eligible for entry into the 18-week continuation study, or who were eligible but elected not to participate, were tapered off study drug at a rate of 1 mg every 7 days for up to a 6-week taper period.

    Also known as: Xanax XR

06

What researchers measure

Primary outcomes

  1. Endpoint change from baseline in the Panic Disorder Severity Scale for Adolescents (PDSS-A) total score

    Time frame: Week 6

  2. Endpoint change from baseline in the weekly frequency of 4-symptom panic attacks

    Time frame: Week 6

Secondary outcomes

  1. Weekly change in the PDSS-A total score

    Time frame: Weeks 1, 2, 3, 4, 5, and 6

  2. Weekly change and endpoint change from baseline in Clinical Global Impression (CGI)-Severity scale

    Time frame: Weeks 1, 2, 3, 4, 5, and 6

  3. Weekly change and endpoint change from baseline in CGI-lmprovement scale

    Time frame: Weeks 1, 2, 3, 4, 5, and 6

  4. Weekly change and and endpoint change from baseline in PDSS-A item scores

    Time frame: Weeks 1, 2, 3, 4, 5, and 6

  5. Endpoint change from baseline in the Hamilton anxiety rating scale total score

    Time frame: Week 6

  6. Endpoint change from baseline in the Children's Depression Rating Scale (CDRS-R) total score

    Time frame: Week 6

  7. Endpoint change from baseline in Pediatric Quality of Life, Enjoyment, Satisfaction Questionnaire

    Time frame: Week 6

  8. Safety assessments will include physical examination, electrocardiogram and laboratory assessments obtained at initial screening, and at the end-of-study visit

    Time frame: Baseline and Week 6

  9. Cognitive and memory effects (free verbal recall test and Digit- Symbol Coding Test)

    Time frame: Baseline and Week 6

  10. Population pharmacokinetic analysis

    Time frame: Weeks 2, 4, and 6

  11. Vital signs

    Time frame: Weeks 1, 2, 3, 4, 5, and 6

07

Study locations

18 sites
  • Pfizer Investigational Site
    Hialeah, Florida 33013, United States
  • Pfizer Investigational Site
    Jacksonville, Florida 32216, United States
  • Pfizer Investigational Site
    North Miami, Florida 33161, United States
  • Pfizer Investigational Site
    Boise, Idaho 83702, United States
  • Pfizer Investigational Site
    Terre Haute, Indiana 47802, United States
  • Pfizer Investigational Site
    New Orleans, Louisiana, United States
  • Pfizer Investigational Site
    Baltimore, Maryland 21208, United States
  • Pfizer Investigational Site
    Saint Paul, Minnesota 55101, United States
  • Pfizer Investigational Site
    Omaha, Nebraska 68131, United States
  • Pfizer Investigational Site
    Lyndhurst, Ohio 44124, United States
  • Pfizer Investigational Site
    Eugene, Oregon 97401, United States
  • Pfizer Investigational Site
    Media, Pennsylvania 19063, United States
  • Pfizer Investigational Site
    Columbia, South Carolina 29201, United States
  • Pfizer Investigational Site
    Lake Jackson, Texas 77566, United States
  • Pfizer Investigational Site
    San Antonio, Texas 78229, United States
  • Pfizer Investigational Site
    Wichita Falls, Texas 76309, United States
  • Pfizer Investigational Site
    Bellevue, Washington 98004, United States
  • Pfizer Investigational Site
    Middleton, Wisconsin 53562, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2004 and a completion of Sep 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2008
First posted
Mar 13, 2008
Start
Apr 2004
CompletionActual
Sep 2004
Last update
Jan 28, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00635531
Responsible party
Sponsor
First posted
Mar 13, 2008
Start date
Apr 2004
Completion
Sep 2004
Last update
Jan 28, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alprazolam

Start the discussion